Tom Randall, reporting for Bloomberg Technology:An experimental cancer treatment that alters the DNA of patients has won a key approval to proceed with its first human tests using the controversial gene-altering tool known as Crispr. Scientists from the University of Pennsylvania want to edit the immune systems of 18 patients to target cancer cells more effectively. The experiment, backed by internet billionaire Sean Parker, won approval from the Recombinant DNA Advisory Committee (RAC), a federal ethics panel set up at the National Institutes of Health 40 years ago to review controversial experiments that change the human genome. The trial still needs final approval from the U.S. Food and Drug Administration. The experiment targets difficult-to-treat cases of multiple myeloma, sarcoma, and melanoma. The scientists will remove blood samples from patients and alter their T-cells -- central to human immune response -- to more effectively target and pursue cancer. The T cells will then be infused back into patients and studied for the safety and effectiveness of the technique.STAT News has an article in which it discusses the probable consequences of altering the DNA of a cancer patient.
#NetNeutrality is STILL in danger - Click here to help. DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Check out the new SourceForge HTML5 Internet speed test. ×